Last reviewed · How we verify
QLS-111, 0.075%
QLS-111, 0.075% is a Small molecule drug developed by Qlaris Bio, Inc.. It is currently in Phase 2 development. Also known as: QLS-111.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | QLS-111, 0.075% |
|---|---|
| Also known as | QLS-111 |
| Sponsor | Qlaris Bio, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation (PHASE2)
- Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients (PHASE2)
- Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLS-111, 0.075% CI brief — competitive landscape report
- QLS-111, 0.075% updates RSS · CI watch RSS
- Qlaris Bio, Inc. portfolio CI
Frequently asked questions about QLS-111, 0.075%
What is QLS-111, 0.075%?
Who makes QLS-111, 0.075%?
Is QLS-111, 0.075% also known as anything else?
What development phase is QLS-111, 0.075% in?
Related
- Manufacturer: Qlaris Bio, Inc. — full pipeline
- Also known as: QLS-111
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing